Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Dr. Carol Farver is a lung pathologist and serves as the Director of Pulmonary Pathology in the Department
of Pathology at the Cleveland Clinic and is Professor of Pathology at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University School of Medicine. She is the past President of the Cleveland Clinic Medical Staff and served on the Cleveland Clinic Board of Governors.
She received her MD degree from Yale University School of Medicine and did her subsequent residency and fellowship/research
training in pulmonary pathology at Brigham and Women’s Hospital and the Harvard School of Public Health in Boston.
She joined the Cleveland Clinic in 1995. She has authored over 115 scientific publications and 30 chapters, primarily in these
areas. She is co-editor of two major textbooks in the field of pulmonary pathology.
Dr. Farver received her M.S. in Organizational Development and Analysis from The Weatherhead School of Management of Case
Western Reserve University and is the Medical Director of the Samson Global Leadership Academy at the Cleveland Clinic.
Dr. Farver is a frequent visiting lecturer on topics of pulmonary pathology, leadership and education. She received the 1st Annual Distinguished Achievement Award in Graduate Medical Education from the National Association of Pathology Chairs, the Scholarship in Teaching Award from Case Western Reserve University School of Medicine, the Cleveland Clinic’s Leadership Development Award and has been included in the “Best Doctors in America” list since 2009.
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 5/10/2016, Dr. Farver has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.